A detailed history of Ashford Capital Management Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ashford Capital Management Inc holds 544,035 shares of SUPN stock, worth $19.7 Million. This represents 2.31% of its overall portfolio holdings.

Number of Shares
544,035
Previous 711,894 23.58%
Holding current value
$19.7 Million
Previous $19 Million 10.92%
% of portfolio
2.31%
Previous 2.82%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$25.77 - $35.16 $4.33 Million - $5.9 Million
-167,859 Reduced 23.58%
544,035 $17 Million
Q2 2024

Aug 15, 2024

SELL
$25.99 - $33.85 $1.34 Million - $1.75 Million
-51,571 Reduced 6.75%
711,894 $19 Million
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $1.71 Million - $2.22 Million
-63,023 Reduced 7.63%
763,465 $26 Million
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $2.05 Million - $2.68 Million
-90,259 Reduced 9.85%
826,488 $23.9 Million
Q3 2023

Nov 15, 2023

SELL
$27.57 - $32.91 $258,165 - $308,169
-9,364 Reduced 1.01%
916,747 $25.3 Million
Q2 2023

Aug 11, 2023

BUY
$29.91 - $38.73 $124,096 - $160,690
4,149 Added 0.45%
926,111 $27.8 Million
Q1 2023

May 15, 2023

SELL
$34.93 - $42.03 $415,247 - $499,652
-11,888 Reduced 1.27%
921,962 $33.4 Million
Q4 2022

Feb 15, 2023

SELL
$31.09 - $37.88 $4.99 Million - $6.08 Million
-160,593 Reduced 14.67%
933,850 $33.3 Million
Q3 2022

Nov 15, 2022

SELL
$28.79 - $35.41 $1.01 Million - $1.24 Million
-34,984 Reduced 3.1%
1,094,443 $37 Million
Q2 2022

Aug 15, 2022

BUY
$25.33 - $34.25 $127,207 - $172,003
5,022 Added 0.45%
1,129,427 $32.7 Million
Q1 2022

May 16, 2022

BUY
$28.51 - $32.9 $1.96 Million - $2.27 Million
68,875 Added 6.53%
1,124,405 $36.3 Million
Q4 2021

Feb 15, 2022

BUY
$26.37 - $34.22 $1.02 Million - $1.33 Million
38,865 Added 3.82%
1,055,530 $30.8 Million
Q3 2021

Nov 15, 2021

BUY
$23.54 - $31.39 $369,413 - $492,603
15,693 Added 1.57%
1,016,665 $27.1 Million
Q2 2021

Aug 26, 2021

SELL
$26.72 - $33.19 $6.15 Million - $7.64 Million
-230,256 Reduced 18.7%
1,000,972 $30.8 Million
Q1 2021

May 14, 2021

BUY
$24.15 - $31.45 $228,869 - $298,051
9,477 Added 0.78%
1,231,228 $32.2 Million
Q4 2020

Feb 16, 2021

BUY
$17.7 - $25.81 $7.16 Million - $10.4 Million
404,247 Added 49.45%
1,221,751 $30.7 Million
Q3 2020

Nov 16, 2020

BUY
$20.2 - $25.05 $2.64 Million - $3.28 Million
130,799 Added 19.05%
817,504 $17 Million
Q2 2020

Aug 17, 2020

BUY
$17.09 - $24.89 $1.89 Million - $2.76 Million
110,701 Added 19.22%
686,705 $16.3 Million
Q1 2020

May 15, 2020

SELL
$14.45 - $24.69 $1.7 Million - $2.9 Million
-117,318 Reduced 16.92%
576,004 $10.4 Million
Q4 2019

Feb 14, 2020

SELL
$19.93 - $29.13 $2.21 Million - $3.24 Million
-111,087 Reduced 13.81%
693,322 $16.4 Million
Q3 2019

Nov 15, 2019

SELL
$25.47 - $33.37 $740,896 - $970,699
-29,089 Reduced 3.49%
804,409 $22.1 Million
Q2 2019

Aug 15, 2019

SELL
$29.96 - $38.87 $101,864 - $132,158
-3,400 Reduced 0.41%
833,498 $27.6 Million
Q1 2019

May 15, 2019

BUY
$32.77 - $41.99 $2.84 Million - $3.64 Million
86,622 Added 11.55%
836,898 $29.3 Million
Q4 2018

Feb 15, 2019

BUY
$30.84 - $49.51 $1.57 Million - $2.52 Million
50,844 Added 7.27%
750,276 $24.9 Million
Q3 2018

Nov 15, 2018

BUY
$42.7 - $56.55 $32,281 - $42,751
756 Added 0.11%
699,432 $35.2 Million
Q2 2018

Aug 15, 2018

SELL
$44.1 - $59.85 $8.03 Million - $10.9 Million
-182,098 Reduced 20.67%
698,676 $41.8 Million
Q1 2018

May 15, 2018

BUY
$37.15 - $46.9 $4.65 Million - $5.87 Million
125,162 Added 16.56%
880,774 $40.3 Million
Q4 2017

Feb 15, 2018

BUY
$36.4 - $42.6 $47,611 - $55,720
1,308 Added 0.17%
755,612 $30.1 Million
Q3 2017

Nov 15, 2017

SELL
$36.75 - $49.65 $67,473 - $91,157
-1,836 Reduced 0.24%
754,304 $30.2 Million
Q2 2017

Aug 21, 2017

BUY
N/A
756,140
756,140 $32.6 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Ashford Capital Management Inc Portfolio

Follow Ashford Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ashford Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ashford Capital Management Inc with notifications on news.